<DOC>
	<DOCNO>NCT00644878</DOCNO>
	<brief_summary>This exploratory study evaluate change molecular response chronic myelogenous leukemia - chronic phase patient complete cytogenetic response suboptimal molecular response imatinib</brief_summary>
	<brief_title>Study Molecular Response Adult Patients Nilotinib With Philadelphia Chromosome Positive Chronic Myelogenous Leukemia ( Ph+ CML ) Chronic Phase Suboptimal Molecular Response Imatinib</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Philadelphia Chromosome</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic-Phase</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Select Male female patient 18 year age confirm diagnosis Ph+ CMLCP CCyR Patients treat imatinib dose 400 mg qd ( least 6 consecutive month Group 1 patient ) A suboptimal molecular response imatinib define : Group 1 : Treated 1 year imatinib , CCyR MMR ( BcrAbl level &gt; 0.1 % IS ) ; Group 2 : No specific duration imatinib require , achieve CCyR &gt; 1 log increase BcrAbl transcript level Adequate end organ function Select Prior accelerate phase blast crisis CML Patients achieve prior CCyR imatinib lose cytogenetic response prior enter study Previously document T315I mutation Prior therapy tyrosine kinase inhibitor except imatinib Patients contraindication receive nilotinib , include concomitant medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>leukemia</keyword>
	<keyword>chronic myelogenous leukemia</keyword>
	<keyword>chronic phase</keyword>
	<keyword>molecular response</keyword>
	<keyword>nilotinib</keyword>
	<keyword>ENABL</keyword>
</DOC>